NEW YORK, April 22, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Walgreen Co. (NYSE: WAG), CVS Caremark Corporation (NYSE: CVS),
Rite Aid Corp. (NYSE: RAD), Cardinal Health, Inc. (NYSE: CAH), and
Chindex International Inc. (NASDAQ: CHDX). Private wealth members
receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Walgreen Co. Analyst Notes
On April 9, 2014, Walgreen Co.
(Walgreens) announced that its board has declared a regular
quarterly dividend of $31.5 per
share, a 14% increase since last year's dividend. According to the
Company, the dividend is payable on June 12,
2014 to shareholders of record as of May 21, 2014. The full analyst notes on Walgreen
Co. are available to download free of charge at:
http://www.AnalystsReview.com/04222014/WAG/report.pdf
--
CVS Caremark Corporation Analyst
Notes
On April 10, 2014, CVS Caremark
Corporation's (CVS Caremark) Insights report cited a 3.8% increase
in prescription drug spending in 2013, compared with 0.1% growth in
2012. The Company stated that in traditional medications, the trend
is a far cry compared with the prescription drug, having only
registered 0.8% growth in 2013, a slight increase from the 3.8%
decline in 2012. According to the Company, this resulted from the
increased demand for specialty drugs treating complex diseases,
which grew by 15.6% in 2013. Jon
Roberts, President, CVS Caremark's Pharmacy Benefit
Management Business, said, "This year's Insights report outlines
seven sure things that our clients should keep in mind. These
include: prescription trend is up, generics have peaked, specialty
drives trend, price is king, money matters to members, adherence is
the answer and past performance is no guarantee of future results."
The full analyst notes on CVS Caremark Corporation are available to
download free of charge at:
http://www.AnalystsReview.com/04222014/CVS/report.pdf
--
Rite Aid Corp. Analyst Notes
On April 10, 2014, Rite Aid Corp.
(Rite Aid) reported its Q4 FY 2014 and full-year FY 2014 financial
results (period ended March 1, 2014).
Q4 2014 revenues increased to $6.6
billion, up 2.2% YoY, and annual revenues slightly increased
to $25.5 billion, up 0.5% YoY.
However, quarterly net income decreased to $55.4 million, or diluted EPS of $0.06, compared with $123.1 million, or diluted EPS of $0.13, in Q4 FY 2013. Meanwhile, annual net
income increased $249.4 million, or
diluted EPS of $0.23, compared with
$118.1 million, or diluted EPS of
$0.12, in full year 2013.
John Standley, Ride Aid Chairman and
CEO, noted that its recent acquisition of Health Dialog and
RediClinic strategically positioned the Company in pursuing
opportunities to becoming a growing retail healthcare company.
"These accomplishments reflect the significant progress we're
making in executing key initiatives and delivering on our promise
to actively work with our customers to keep them well," Standley
added. The full analyst notes on Rite Aid Corp. are available to
download free of charge at:
http://www.AnalystsReview.com/04222014/RAD/report.pdf
--
Cardinal Health, Inc. Analyst Notes
On April 10, 2014, Cardinal
Health, Inc. (Cardinal Health) announced that it will release its
Q3 FY 2014 financial results on May 1,
2014, before the opening of trading on the New York Stock
Exchange. The Company informed that it will also broadcast the
results via webcast and conference call that same day at
8:30 a.m. ET. Presentation slides
will be archived on the Company's website, as well as the audio
replay, which will only be available for seven days after the
presentation. The full analyst notes on Cardinal Health, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04222014/CAH/report.pdf
--
Chindex International Inc. Analyst Notes
On April 14, 2014, Chindex
International Inc. (Chindex) announced its receipt of offer from a
financial bidder to acquire all of the Company's outstanding common
stock shares for $23 per share in
cash. The Company's committee of independent directors advised the
bidder to submit a superior proposal. In addition, the definitive
terms and conditions for the merger agreement is subjected by
execution of the Company, and is not subject to any financing
condition that any existing stockholders of the Company participate
in the merger by rolling over equity, or entering into a voting
agreement. The full analyst notes on Chindex International Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04222014/CHDX/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review